Tag: ISLA-101
Island Pharmaceuticals announces completion of ISLA-101 dosing study
In a significant development in the fight against dengue fever, Island Pharmaceuticals Ltd (ASX: ILA), a leading Australian antiviral drug development company, has announced the ... Read More
Island Pharmaceuticals advances in dengue treatment: Completes second phase of ISLA-101 study
Australia-based Island Pharmaceuticals Ltd (ASX: ILA) has achieved a significant milestone in its quest to combat mosquito-borne diseases, particularly dengue. The company announced the successful ... Read More
Island Pharmaceuticals commences key dengue fever drug trial in Australia
Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA), has reached a milestone with the commencement of its Single Ascending Dose (SAD) study for ... Read More